Main researchers

SERGIO LAVANDERO Research line: Metabolism and Director Cardiovascular signaling ACCDiS | University of Chile | e-mail

Sergio Lavandero is a Chilean researcher with national and international recognition. Is currently Professor Dela Faculty of chemical and pharmaceutical sciences and the Faculty of medicine, University of Chile. He is also adjunct professor in the Division of Cardiology, University of Texas Southwestern Medical Center (Dallas, Texas) and he serves as Director and senior researcher at the Center for advanced chronic diseases (ACCDiS ). Dr. Lavandero has published 205 articles journals indexed international (total citations: 8.562;h-index: 39). Their investigations have been supported by FONDECYT projects, Anillo, FONDAP and international collaboration. It integrates the editorial committees of Am J Physiol Endocrinology journals & Metabolism and Cell Death & Diseases and has been a reviewer tod hoc of prestigious international journals and national and international agencies that support scientific research. He has directed 70 memories of undergraduate, 63 and 7 master's doctoral thesis as also to 10 post-doc researchers. Their most important administrative positions have been: President and CEO of biology in the Superior Council of science, CONICYT, President of the Chilean society of Biochemistry and Molecular Biology, Member of the Council for evaluation and Vice-Rector of research of the University of Chile. He is currently a member of the Chilean Academy of Sciences.

CATTERINA FERRECCIO Research line: Deputy Director ACCDiS | Pontificia Universidad Católica de Chile | e-mail:

Catterina Ferreccio MD, MSP, the University of Chile and MSP in epidemiology, the Johns Hopkins University.

Professor and Director of the master program in epidemiology. Department of health public of the Faculty of Medicine of the Pontifical University Catholic of Chile (UC).

Area of interest: Prevention and control of cancers associated with infectious and environmental causes in Chile.

Work: From 2014 the Advanced Center Deputy Director of chronic diseases (ACCDiS for its acronym in English). From 1990 to date Professor of public health, Faculty of Medicine of the UC. 2000-2002 Regional Consultant of PAHO in Washington DC, on operational research related to cervical cancer in Peru, Chile and El Salvador. Assistant Professor of Center Investigación of vaccine development from the University of Maryland, School of medicine. General practitioner, Talagante, Chile.

Collaborations and international committees

Group of the who study on burden of food-borne diseases, Advisory Committee of immunization in Chile. He has been scientific visitor at: IARC, Lyon, the National Cancer Institute, NIH / USA; School of public health. University of California at Berkeley. And President of the Chilean society of epidemiology.

Current research: primary and secondary prevention of stomach cancer. Natural history of gallbladder cancer. Long term effects of exposure to arsenic in drinking water. Field of the alternatives of cervical cancer detection tests. Home of a large population-based cohort to study the emergence of chronic diseases and cancer.

Publications: 134 in peer-review journals

Financing: Fondecyt, Fondef, EE. UU. EPA, the who, the NIH, Bill and Melinda Gates.

ANDREW QUEST Research line: La inflamación en la angiogénesis, cell migration and metastasis. University of Chile | e-mail

Andrew Quest is Magister (1983) and doctor (1988) in Biochemistry from the Federal Institute of technology in Switzerland, Zurich. Then, He trained as a postdoctoral fellow with Dr. Ben Shapiro (Department of Biochemistry at the University of Washington, Seattle, WA, USA) in the study of protein-lipid modifications (1988-1990) and then with Dr. Robert M. Campaign (Department of Biochemistry, Duke University, Durham, North Carolina, USA) investigated the regulation of lipids, protein kinase C-dependent (1990-1994).

He was adjunct professor at the Institute of biochemistry of the University of Lausanne, Switzerland (1994-1999), where he studied the role of membrane microdomains (rafts, caveolae) in the cellular signaling and cancer. Then, He moved to the Institute of Biomedical Sciences (ICBM), University of Chile, Chile (1999 to date).

Andrew currently holds the position of Professor. Projects in our laboratory are funded by national programmes (FONDECYT / FONDAP / PIA). In addition, It is one of the six principal investigators who founded the FONDAP Center of molecular studies of cell (CEMC) in the year 2002, the basic cellular mechanisms in the physiology and pathology survey. He is currently the Director of CEMC, that it continues to pursue similar research objectives and promote advanced human resources training to provide opportunities of research for students at all levels; undergraduate, Graduate, Postgraduate, as well as the favorable conditions for the inclusion of academic youth in Chile research system. In addition, He is director of the metabolic stress of signaling network (NEMESIS) It evaluates the molecular mechanisms that underlie the development of chronic diseases in Chile (see the web site Finally, is principal investigator and Chief Scientist (area of cancer) of the Centre for advanced chronic diseases (ACCDiS ), where, next six researchers, they study the mechanisms leading to the development of cardiovascular diseases and cancer.

ALEJANDRO CORVALAN Research line: Biomarkers for the early detection of cancer Pontifical Catholic University of Chile | e-mail

Alejandro Corvalan is Associate Professor of the Faculty of Medicine of the Pontificia Universidad Católica de Chile, Santiago, Chile. President cancer cooperative group Chilean research (GOCCHI), Santiago de Chile Director Center UC research in Oncology (CITO), Pontificia Universidad Católica de Chile, Santiago, Chile and principal investigator for the Center for advanced chronic diseases (ACCDiS ).

The laboratory of Dr. Corvalan is involved in translational research for cancer at levels Basic, clinical and population. Your inquiries are mainly focused on epigenetics of cancer, with emphasis on the discovery and validation of inactivated by methylation tumor suppressor genes and microRNAs DNA. These findings act as potential biomarkers for early diagnosis of cancer, monitoring response to treatment and the development of new treatments. Through this research, We are developing new potential biomarkers for early detection of gastric cancer, cell-free plasma DNA-based (NCT01774266). It is also the role of EBV and the role of coding and non-coding genes in the pathogenesis of cancer.

MARCELO KOGAN Research line: Nanomedicine and Nanoteranostica University of Chile | e-mail

Marcelo J. Kogan is biochemist and pharmacist of the University of Buenos Aires and PhD in organic chemistry from the same University. He was awarded two postdoctoral fellowships from the Government of Spain. It is also, Professor in the Department of Pharmacology and toxicology of the Faculty of chemical sciences and pharmaceutical of the University of Chile, and principal investigator at the Center for advanced chronic diseases (ACCDiS ). The director of the laboratory of nanomedicine and Nanoteranostica in this Center. In 2006 he was a visiting professor at the University of Texas, Medical Branch, and in 2002 a visiting professor at the University of Barcelona.

His interest is focused on nanobiomateriales applications in biomedicine for the diagnosis and treatment of conformational diseases involving the administration of drugs, such as Alzheimer's, cancer and cardiovascular diseases. Marcelo Kogan is a pioneer in the field of the use of nanoparticles for the breakdown of the amyloid (Kogan et al, Nanoletters, 1110, 2006). He has published more than 60 articles in ISI Journals, 10 comments, and four books of chapters. He has been invited to present around 30 conferences at international meetings. He has directed 20 Ph.d. theses and has participated in more than 70 papers. In addition, It has belonged to various organizing committees of international meetings.

pablo castro

PABLO CASTRO Research line: Emerging biomarkers in heart failure Pontificia Universidad Católica de Chile | e-mail